You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCitric Acid
Accession NumberDB04272  (EXPT00922)
TypeSmall Molecule
GroupsNutraceutical
Description

A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability. [PubChem]

Structure
Thumb
Synonyms
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Citronensäure
External Identifiers Not Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Stop Hairspray7 mg/mLtopicalMila Beauty Pty Ltd2012-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Stop Hairspray.7 mg/100mLtopicalStop Hair Pty Ltd2012-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Whitening Lemon Peelliquid.007 g/mLtopicalAmi Cosmetic Co.,Ltd.2013-08-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Acd ATerumo Bct Ltd
Acd-AHaemonetics Manufacturing Inc
Alka Seltzer EvtMiles Canada Inc. Consumer Health Care Division
Alka Seltzer FlavouredMiles Canada Inc. Consumer Health Care Division
Alka-seltzerBayer Inc Consumer Care
Alka-seltzer FlavouredBayer Inc Consumer Care
Alka-seltzer Flavoured - EvtBayer Inc Consumer Care
Alka-seltzer GoldBayer Health Care Consumer Care
Anticoagulant Citrate Dextrose A Acd-AArteriocyte Medical Systems, Inc.
As 3Terumo Bct Ltd
BicaruvasProsana Distribuciones, S.A. De C.V.
Bromo SeltzerTower Laboratories Ltd
CitracleenLaboratorios Casen Fleet, S.L.U.
Citrocarbonate Eff PwsRoberts Pharmaceutical Canada Inc.
Cpda-1Fenwal, Inc.
Cpda-1 Blood Collection SystemHaemonetics Manufacturing Inc
Cytra-K CrystalsCypress Pharmaceutical, Inc.
Effervescent Pain ReliefWestern Family Foods, Inc.
Effervescent Pain Relief Fast ReliefDeseret Laboratories, Inc.
Effervescent Pain Relief Fast Relief Fast ReliefMajor Pharmaceuticals
Haemonetics Additive Solution Formula 3 (as-3)Haemonetics Corporation
Haemonetics Anticoagulant Citrate Phosphate Double Dextrose Solution (cp2d)Haemonetics Corporation
Heparin Sodium 1000units In 0.9% Sodium Chloride Injection USPB. Braun Medical Inc
Leukotrap Wb SystemHaemonetics Manufacturing Inc
Lytren Rhs LiqMead Johnson Nutritionals
Medique Medi SeltzerUnifirst First Aid Corporation
Neutra-seltzerTeva Canada Limited
Nutricel Additive System - As-3Medsep Corporation
Nutricel Additive System - Cp2dMedsep Corporation
OracitCarolina Medical Products Company
Oral PurgativeOdan Laboratories Ltd
Pain Relief Fast ReliefSelect Brand
Pico-salaxFerring Inc
PicodanOdan Laboratories Ltd
PicofloPharmascience Inc
Picot Plus EffervescentBristol Myers Squibb De Mexico, S. De R.L. De C.V.
Potassium Citrate and Citric AcidPharmaceutical Associates, Inc.
Potassium Citrate Citric Acid CrystalsVirtus Pharmaceuticals LLC
Potassium Citrate-citric AcidMethod Pharmaceuticals, Llc
Potassium Citrate-sodium Citrate-citric AcidMethod Pharmaceuticals, Llc
Premier Value Antacid and Pain Relief MedicineChain Drug Consortium, LLC
Purg-odanOdan Laboratories Ltd
RenacidinGuardian Laboratories, Division Of United Guardian Inc.
Sal De Uvas PicotBristol Myers Squibb De Mexico, S. De R.L. De C.V.
Sodium Citrate and Citric AcidPharmaceutical Associates, Inc.
Sodium Citrate-citric AcidMethod Pharmaceuticals, Llc
Sterile Cord Blood Collection UnitMedsep Corporation
TricitratesPharmaceutical Associates, Inc.
Vida Mia Pain ReliefNavarro Discount Pharmacies, LLC
Zee-seltzer Antacid and Pain RelieverZEE MEDICAL
Salts
Name/CASStructureProperties
Citric acid monohydrate
ThumbNot applicableDBSALT001502
Categories
UNIIXF417D3PSL
CAS number77-92-9
WeightAverage: 192.1235
Monoisotopic: 192.02700261
Chemical FormulaC6H8O7
InChI KeyInChIKey=KRKNYBCHXYNGOX-UHFFFAOYSA-N
InChI
InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
IUPAC Name
2-hydroxypropane-1,2,3-tricarboxylic acid
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassTricarboxylic acids and derivatives
Direct ParentTricarboxylic acids and derivatives
Alternative Parents
Substituents
  • Tricarboxylic acid or derivatives
  • Beta-hydroxy acid
  • Hydroxy acid
  • Alpha-hydroxy acid
  • Tertiary alcohol
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityORAL (LD50): Acute: 5040 mg/kg [Mouse]. 3000 mg/kg [Rat].
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7518
Blood Brain Barrier+0.855
Caco-2 permeable-0.8634
P-glycoprotein substrateNon-substrate0.6125
P-glycoprotein inhibitor INon-inhibitor0.9694
P-glycoprotein inhibitor IINon-inhibitor0.9658
Renal organic cation transporterNon-inhibitor0.9624
CYP450 2C9 substrateNon-substrate0.8641
CYP450 2D6 substrateNon-substrate0.8932
CYP450 3A4 substrateNon-substrate0.6809
CYP450 1A2 substrateNon-inhibitor0.9336
CYP450 2C9 inhibitorNon-inhibitor0.9399
CYP450 2D6 inhibitorNon-inhibitor0.9476
CYP450 2C19 inhibitorNon-inhibitor0.9396
CYP450 3A4 inhibitorNon-inhibitor0.8735
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9904
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8206
BiodegradationReady biodegradable0.6288
Rat acute toxicity1.7748 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9948
hERG inhibition (predictor II)Non-inhibitor0.9577
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet (effervescent)oral
Tablet, effervescentoral
Injection, solutionextracorporeal
Injection, solutionintravenous
Granulesoral
Powder (effervescent)oral
Solutionintravenous
Granule, for solutionoral
Solutionextracorporeal
Liquidoral
Powder for solutionoral
Powderoral
Powder for solutionirrigation; topical
Powder, for solutionoral
Solutionoral
Spraytopical.7 mg/100mL
Spraytopical7 mg/mL
Liquidtopical.007 g/mL
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point153 °CPhysProp
water solubility5.92E+005 mg/L (at 20 °C)MERCK INDEX (1989)
logP-1.64AVDEEF,A (1997)
logS0.51ADME Research, USCD
pKa2.79SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility106.0 mg/mLALOGPS
logP-1.3ALOGPS
logP-1.3ChemAxon
logS-0.26ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area132.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity35.62 m3·mol-1ChemAxon
Polarizability15.54 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-3zh5000000-c310fda0e6a19bf6ae40View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-2zg4000000-f1dfda3e9abc7cfb6b2aView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-1zk9100000-ba3a1a80815f65afd05cView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-2zj6000000-48857e9baebe16d9fc8dView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-zmd4000000-b6fd7d038634694f0873View in MoNA
GC-MSGC-MS Spectrum - GC-MS (4 TMS)splash10-3mzf100000-b193bbba8c0cefdfe42aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Negative (Annotated)splash10-az00000000-956001b034bbc0b7da96View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Negative (Annotated)splash10-z600000000-55e34e2c1616942fd4f2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Negative (Annotated)splash10-z200000000-7b8be3e90a4daf85f04aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-0z75a31100-af80d22f720facc4813aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-z000000000-6f4fedbb19821898fb22View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-0z00000000-8eff68ab89f7ce2262beView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-006zb00000-b370c4c3dd656c8eb729View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-0z59611000-05e8ceb6dd97f7b9af98View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-z000000000-e4b67745443c48a63bd6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-0z00000000-92536abec982e0a653a0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negativesplash10-07z3000000-35772df08490f451d828View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-0z00000000-35856cc258368d13e1ffView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-dz00000000-7170fdcb9749e6d6c2fbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-zm00000000-9a502981b0a9e1ea35adView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-z700000000-ed0c86b90e1f4966d025View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-z100000000-b8a975c2d639d8c91afbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negativesplash10-8z00000000-30970a4250098e148658View in MoNA
MSMass Spectrum (Electron Ionization)splash10-zg00000000-fb757b614278bb898b54View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,1H] 2D NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Karl E. Wiegand, “Chemical process for producing citric acid.” U.S. Patent US3962287, issued 0000.

US3962287
General ReferencesNot Available
External Links
ATC CodesA09AB04
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (49.5 KB)
Interactions
Drug Interactions
Drug
AbciximabAbciximab may increase the anticoagulant activities of Citric Acid.
AcenocoumarolCitric Acid may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Citric Acid.
AlteplaseAlteplase may increase the anticoagulant activities of Citric Acid.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Citric Acid.
AnagrelideAnagrelide may increase the anticoagulant activities of Citric Acid.
ApixabanApixaban may increase the anticoagulant activities of Citric Acid.
ArgatrobanCitric Acid may increase the anticoagulant activities of Argatroban.
Bismuth SubsalicylateBismuth Subsalicylate may increase the anticoagulant activities of Citric Acid.
BivalirudinCitric Acid may increase the anticoagulant activities of Bivalirudin.
CaffeineCaffeine may increase the anticoagulant activities of Citric Acid.
CangrelorCangrelor may increase the anticoagulant activities of Citric Acid.
CelecoxibCelecoxib may increase the anticoagulant activities of Citric Acid.
CilostazolCilostazol may increase the anticoagulant activities of Citric Acid.
CitalopramCitalopram may increase the anticoagulant activities of Citric Acid.
ClopidogrelClopidogrel may increase the anticoagulant activities of Citric Acid.
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Citric Acid is combined with Collagenase clostridium histolyticum.
Cyproterone acetateThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Cyproterone acetate.
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Citric Acid.
DalteparinCitric Acid may increase the anticoagulant activities of Dalteparin.
DanaparoidCitric Acid may increase the anticoagulant activities of Danaparoid.
DasatinibDasatinib may increase the anticoagulant activities of Citric Acid.
DeferasiroxThe risk or severity of adverse effects can be increased when Citric Acid is combined with Deferasirox.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Deoxycholic Acid.
DesirudinCitric Acid may increase the anticoagulant activities of Desirudin.
DesogestrelDesogestrel may decrease the anticoagulant activities of Citric Acid.
DesvenlafaxineDesvenlafaxine may increase the anticoagulant activities of Citric Acid.
DiclofenacDiclofenac may increase the anticoagulant activities of Citric Acid.
DienogestThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Dienogest.
DiflunisalDiflunisal may increase the anticoagulant activities of Citric Acid.
DihydrocodeineDihydrocodeine may increase the anticoagulant activities of Citric Acid.
DipyridamoleDipyridamole may increase the anticoagulant activities of Citric Acid.
DrospirenoneDrospirenone may decrease the anticoagulant activities of Citric Acid.
DuloxetineDuloxetine may increase the anticoagulant activities of Citric Acid.
EdoxabanEdoxaban may increase the anticoagulant activities of Citric Acid.
EnoxaparinCitric Acid may increase the anticoagulant activities of Enoxaparin.
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Citric Acid.
EptifibatideEptifibatide may increase the anticoagulant activities of Citric Acid.
EscitalopramEscitalopram may increase the anticoagulant activities of Citric Acid.
EstradiolEstradiol may decrease the anticoagulant activities of Citric Acid.
EstropipateEstropipate may decrease the anticoagulant activities of Citric Acid.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Citric Acid.
EthynodiolEthynodiol may decrease the anticoagulant activities of Citric Acid.
EtodolacEtodolac may increase the anticoagulant activities of Citric Acid.
EtonogestrelThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Etonogestrel.
FenoprofenFenoprofen may increase the anticoagulant activities of Citric Acid.
FloctafenineFloctafenine may increase the anticoagulant activities of Citric Acid.
FluoxetineFluoxetine may increase the anticoagulant activities of Citric Acid.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Citric Acid.
FluvoxamineFluvoxamine may increase the anticoagulant activities of Citric Acid.
Fondaparinux sodiumCitric Acid may increase the anticoagulant activities of Fondaparinux sodium.
HeparinCitric Acid may increase the anticoagulant activities of Heparin.
Hydroxyprogesterone caproateThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Hydroxyprogesterone caproate.
IbritumomabThe risk or severity of adverse effects can be increased when Citric Acid is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Citric Acid.
IbuprofenIbuprofen may increase the anticoagulant activities of Citric Acid.
IcosapentIcosapent may increase the anticoagulant activities of Citric Acid.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Citric Acid.
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Citric Acid.
IndomethacinIndomethacin may increase the anticoagulant activities of Citric Acid.
KetoprofenKetoprofen may increase the anticoagulant activities of Citric Acid.
KetorolacKetorolac may increase the anticoagulant activities of Citric Acid.
LevomilnacipranLevomilnacipran may increase the anticoagulant activities of Citric Acid.
LevonorgestrelThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Levonorgestrel.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Citric Acid.
Medroxyprogesterone AcetateThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Medroxyprogesterone Acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Citric Acid.
Megestrol acetateThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Citric Acid.
MestranolMestranol may decrease the anticoagulant activities of Citric Acid.
MilnacipranMilnacipran may increase the anticoagulant activities of Citric Acid.
NabumetoneNabumetone may increase the anticoagulant activities of Citric Acid.
NadroparinCitric Acid may increase the anticoagulant activities of Nadroparin.
NaproxenNaproxen may increase the anticoagulant activities of Citric Acid.
NintedanibThe risk or severity of adverse effects can be increased when Citric Acid is combined with Nintedanib.
NorethindroneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Norethindrone.
NorgestimateNorgestimate may decrease the anticoagulant activities of Citric Acid.
ObinutuzumabThe risk or severity of adverse effects can be increased when Citric Acid is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Citric Acid.
Omega-3-acid ethyl estersOmega-3-acid ethyl esters may increase the anticoagulant activities of Citric Acid.
OxaprozinOxaprozin may increase the anticoagulant activities of Citric Acid.
ParoxetineParoxetine may increase the anticoagulant activities of Citric Acid.
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Citric Acid.
PiroxicamPiroxicam may increase the anticoagulant activities of Citric Acid.
PrasugrelPrasugrel may increase the anticoagulant activities of Citric Acid.
ProgesteroneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Progesterone.
ReteplaseReteplase may increase the anticoagulant activities of Citric Acid.
RivaroxabanCitric Acid may increase the anticoagulant activities of Rivaroxaban.
SalsalateSalsalate may increase the anticoagulant activities of Citric Acid.
SertralineSertraline may increase the anticoagulant activities of Citric Acid.
SulindacSulindac may increase the anticoagulant activities of Citric Acid.
TenecteplaseTenecteplase may increase the anticoagulant activities of Citric Acid.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Citric Acid.
TicagrelorTicagrelor may increase the anticoagulant activities of Citric Acid.
TiclopidineTiclopidine may increase the anticoagulant activities of Citric Acid.
TinzaparinCitric Acid may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the anticoagulant activities of Citric Acid.
TirofibanTirofiban may increase the anticoagulant activities of Citric Acid.
TolmetinTolmetin may increase the anticoagulant activities of Citric Acid.
TositumomabThe risk or severity of adverse effects can be increased when Citric Acid is combined with Tositumomab.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Citric Acid.
VenlafaxineVenlafaxine may increase the anticoagulant activities of Citric Acid.
VilazodoneVilazodone may increase the anticoagulant activities of Citric Acid.
Vitamin EVitamin E may increase the anticoagulant activities of Citric Acid.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Citric Acid.
VortioxetineVortioxetine may increase the anticoagulant activities of Citric Acid.
WarfarinCitric Acid may increase the anticoagulant activities of Warfarin.
Food InteractionsNot Available

Targets

1. Cell division protein FtsZ

Kind: Protein

Organism: Mycobacterium tuberculosis

Pharmacological action: unknown

Components

Name UniProt ID Details
Cell division protein FtsZ P64170 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

2. Angiogenin

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Angiogenin P03950 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

3. Beta-lactamase 2

Kind: Protein

Organism: Bacillus cereus

Pharmacological action: unknown

Components

Name UniProt ID Details
Beta-lactamase 2 P04190 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Uridine-cytidine kinase 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Uridine-cytidine kinase 2 Q9BZX2 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

5. Tumor necrosis factor ligand superfamily member 13B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Tumor necrosis factor ligand superfamily member 13B Q9Y275 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

6. Betaine--homocysteine S-methyltransferase 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Betaine--homocysteine S-methyltransferase 1 Q93088 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

7. Tryptophan--tRNA ligase

Kind: Protein

Organism: Geobacillus stearothermophilus

Pharmacological action: unknown

Components

Name UniProt ID Details
Tryptophan--tRNA ligase P00953 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

8. Aldose reductase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Aldose reductase P15121 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

9. Citrate synthase, mitochondrial

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Citrate synthase, mitochondrial O75390 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

10. Heparan sulfate glucosamine 3-O-sulfotransferase 3A1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 Q9Y663 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

11. cGMP-specific 3',5'-cyclic phosphodiesterase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
cGMP-specific 3',5'-cyclic phosphodiesterase O76074 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

12. Proto-oncogene tyrosine-protein kinase Src

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Proto-oncogene tyrosine-protein kinase Src P12931 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

13. Ribonuclease pancreatic

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Ribonuclease pancreatic P07998 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

14. Isocitrate dehydrogenase [NADP]

Kind: Protein

Organism: Bacillus subtilis (strain 168)

Pharmacological action: unknown

Components

Name UniProt ID Details
Isocitrate dehydrogenase [NADP] P39126 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

15. Glycine N-methyltransferase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Glycine N-methyltransferase Q14749 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

16. Eosinophil cationic protein

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Eosinophil cationic protein P12724 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

17. Beta-lactamase

Kind: Protein

Organism: Bacillus licheniformis

Pharmacological action: unknown

Components

Name UniProt ID Details
Beta-lactamase P00808 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

18. Molybdenum cofactor guanylyltransferase

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
Molybdenum cofactor guanylyltransferase P32173 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

19. Fumarate hydratase class II

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
Fumarate hydratase class II P05042 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

20. 6-phosphogluconolactonase

Kind: Protein

Organism: Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

Pharmacological action: unknown

Components

Name UniProt ID Details
6-phosphogluconolactonase Q9X0N8 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

21. Oxygen-insensitive NAD(P)H nitroreductase

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
Oxygen-insensitive NAD(P)H nitroreductase P38489 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

22. Gag-Pro-Pol polyprotein

Kind: Protein

Organism: RSV-SRA

Pharmacological action: unknown

Components

Name UniProt ID Details
Gag-Pro-Pol polyprotein Q04095 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

23. L-amino-acid oxidase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
L-amino-acid oxidase Q96RQ9 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

24. Macrophage migration inhibitory factor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Macrophage migration inhibitory factor P14174 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

25. Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Q9GZU7 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

26. 1-deoxy-D-xylulose 5-phosphate reductoisomerase

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
1-deoxy-D-xylulose 5-phosphate reductoisomerase P45568 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

27. Tryptophan synthase alpha chain

Kind: Protein

Organism: Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)

Pharmacological action: unknown

Components

Name UniProt ID Details
Tryptophan synthase alpha chain P16608 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

28. Sialidase

Kind: Protein

Organism: Micromonospora viridifaciens

Pharmacological action: unknown

Components

Name UniProt ID Details
Sialidase Q02834 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

29. KHG/KDPG aldolase

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
KHG/KDPG aldolase P0A955 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

30. Cytochrome c peroxidase

Kind: Protein

Organism: Marinobacter hydrocarbonoclasticus

Pharmacological action: unknown

Components

Name UniProt ID Details
Cytochrome c peroxidase P83787 Details

31. Hepatocyte growth factor-regulated tyrosine kinase substrate

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Hepatocyte growth factor-regulated tyrosine kinase substrate O14964 Details

References:

  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

32. Invasin

Kind: Protein

Organism: Yersinia pseudotuberculosis serotype I (strain IP32953)

Pharmacological action: unknown

Components

Name UniProt ID Details
Invasin P11922 Details

33. Intron-associated endonuclease 1

Kind: Protein

Organism: Enterobacteria phage T4

Pharmacological action: unknown

Components

Name UniProt ID Details
Intron-associated endonuclease 1 P13299 Details

34. Short tail fiber protein

Kind: Protein

Organism: Enterobacteria phage T4

Pharmacological action: unknown

Components

Name UniProt ID Details
Short tail fiber protein gp12 P10930 Details

35. Malate dehydrogenase, mitochondrial

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Malate dehydrogenase, mitochondrial P40926 Details

References:

  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

36. N5-carboxyaminoimidazole ribonucleotide mutase

Kind: Protein

Organism: Acetobacter aceti

Pharmacological action: unknown

Components

Name UniProt ID Details
N5-carboxyaminoimidazole ribonucleotide mutase Q2QJL3 Details

37. 50S ribosomal protein L4

Kind: Protein

Organism: Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

Pharmacological action: unknown

Components

Name UniProt ID Details
50S ribosomal protein L4 P38516 Details

38. Carboxypeptidase B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Carboxypeptidase B P15086 Details

39. Hexon protein

Kind: Protein

Organism: HAdV-2

Pharmacological action: unknown

Components

Name UniProt ID Details
Hexon protein P03277 Details

40. Riboflavin biosynthesis protein RibF

Kind: Protein

Organism: Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

Pharmacological action: unknown

Components

Name UniProt ID Details
Riboflavin biosynthesis protein Q9WZW1 Details

41. Beta-fructosidase

Kind: Protein

Organism: Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

Pharmacological action: unknown

Components

Name UniProt ID Details
Beta-fructosidase O33833 Details

42. Putative stringent starvation protein A

Kind: Protein

Organism: Yersinia pestis

Pharmacological action: unknown

Components

Name UniProt ID Details
Putative stringent starvation protein A Q7CL96 Details

43. Citrate synthase

Kind: Protein

Organism: Thermus thermophilus

Pharmacological action: unknown

Components

Name UniProt ID Details
Citrate synthase Q9LCX9 Details

44. RNA 3'-terminal phosphate cyclase

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
RNA 3'-terminal phosphate cyclase P46849 Details

45. U6 snRNA-associated Sm-like protein LSm6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
U6 snRNA-associated Sm-like protein LSm6 P62312 Details

References:

  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

46. Pleckstrin homology domain-containing family A member 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Pleckstrin homology domain-containing family A member 1 Q9HB21 Details

47. Fe(3+)-binding periplasmic protein

Kind: Protein

Organism: Serratia marcescens

Pharmacological action: unknown

Components

Name UniProt ID Details
Fe(3+)-binding periplasmic protein P21408 Details

48. Signal recognition particle receptor FtsY

Kind: Protein

Organism: Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

Pharmacological action: unknown

Components

Name UniProt ID Details
Signal recognition particle receptor FtsY Q9WZ40 Details

49. Nicotinate-nucleotide adenylyltransferase

Kind: Protein

Organism: Shigella flexneri

Pharmacological action: unknown

Components

Name UniProt ID Details
Nicotinate-nucleotide adenylyltransferase P0A753 Details

50. N utilization substance protein B homolog

Kind: Protein

Organism: Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

Pharmacological action: unknown

Components

Name UniProt ID Details
N utilization substance protein B homolog Q9X286 Details

51. Complement component C8 gamma chain

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement component C8 gamma chain P07360 Details

52. Ribonucleoside-diphosphate reductase subunit beta

Kind: Protein

Organism: Mycobacterium leprae (strain TN)

Pharmacological action: unknown

Components

Name UniProt ID Details
Ribonucleoside-diphosphate reductase subunit beta Q9CBQ2 Details

53. Glutamine synthetase 1

Kind: Protein

Organism: Mycobacterium tuberculosis

Pharmacological action: unknown

Components

Name UniProt ID Details
Glutamine synthetase 1 P0A590 Details

54. Citrate synthase

Kind: Protein

Organism: Antarctic bacterium DS2-3R

Pharmacological action: unknown

Components

Name UniProt ID Details
2-methylcitrate synthase O34002 Details

55. Prostaglandin F synthase

Kind: Protein

Organism: Trypanosoma brucei brucei

Pharmacological action: unknown

Components

Name UniProt ID Details
Prostaglandin F synthase Q9GV41 Details

56. Adenine phosphoribosyltransferase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Adenine phosphoribosyltransferase P07741 Details

References:

  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

57. Glucose-1-phosphate thymidylyltransferase

Kind: Protein

Organism: Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)

Pharmacological action: unknown

Components

Name UniProt ID Details
Glucose-1-phosphate thymidylyltransferase Q9HU22 Details

58. Glyoxalase family protein

Kind: Protein

Organism: Bacillus cereus (strain ATCC 14579 / DSM 31)

Pharmacological action: unknown

Components

Name UniProt ID Details
Glyoxalase family protein Q81F54 Details

59. Laccase domain protein YfiH

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
Laccase domain protein YfiH P33644 Details

60. Ribose-5-phosphate isomerase A

Kind: Protein

Organism: Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)

Pharmacological action: unknown

Components

Name UniProt ID Details
Ribose-5-phosphate isomerase A P44725 Details

61. GMP synthase [glutamine-hydrolyzing]

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: unknown

Components

Name UniProt ID Details
GMP synthase [glutamine-hydrolyzing] P04079 Details

62. Inosine triphosphate pyrophosphatase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Inosine triphosphate pyrophosphatase Q9BY32 Details

References:

  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

63. Lysozyme

Kind: Protein

Organism: Enterobacteria phage P1

Pharmacological action: unknown

Components

Name UniProt ID Details
Lysozyme Q37875 Details

64. Glycerol uptake operon antiterminator regulatory protein

Kind: Protein

Organism: Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

Pharmacological action: unknown

Components

Name UniProt ID Details
Glycerol uptake operon antiterminator regulatory protein Q9X1F0 Details

65. 3-carboxy-cis,cis-muconate cycloisomerase

Kind: Protein

Organism: Pseudomonas putida

Pharmacological action: unknown

Components

Name UniProt ID Details
3-carboxy-cis,cis-muconate cycloisomerase P32427 Details

66. Pyruvate decarboxylase

Kind: Protein

Organism: Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)

Pharmacological action: unknown

Components

Name UniProt ID Details
Pyruvate decarboxylase P06672 Details

Transporters

1. Solute carrier organic anion transporter family member 2B1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 2B1 O94956 Details

References:

  1. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2015 09:51